PsycApps

Market position

PsycApps competes in the digital mental health and wellbeing market, targeting preventative and early-intervention use cases in education and the workplace at a time of long NHS waiting times and rising demand for digital mental health services. Coverage notes that clinical trial evidence helps it secure school and college contracts and that low user engagement is a recognised weakness of mental health apps generally, which its investor cited as a reason for backing eQuoo's engagement and outcomes data.

The company positions eQuoo as one of a small minority of apps (cited as the exclusive 2% of apps) clinically proven to enhance resilience and reduce depression and anxiety, and claims to be the only tool covered by Ofsted requirements with clinical trials demonstrating positive impact on students' resilience, anxiety and depression. Management argues that the combination of clinical validation, gamified engagement mechanics suited to a largely casual-gaming young-adult audience, and indefinite scalability creates a barrier to entry for competing programmes that are neither evidence-based nor scalable.

Technology

eQuoo is a gamified, choice-driven narrative platform delivered as a mobile app and a browser-based web version for classroom use, incorporating multiple storylines, an in-app arcade of mental health exercises, real-time progress tracking and clinical chatbots that benchmark wellbeing and route users to targeted support. An analytics dashboard lets institutional staff review outcome data and trends.

Go-to-market

Sales are focused on educational institutions and employers, aided by UK regulatory drivers: Ofsted requires schools and colleges to include a resilience and personal development programme to achieve a top rating, and higher education institutions have duties around student wellbeing. The company markets clinical validation as a procurement requirement it can satisfy, runs demo bookings and contact forms for institutional enquiries, operates a referrer programme, and uses content marketing through blogs, webinars, podcasts and a newsletter.

Secondary schools, colleges, universities and apprenticeship providers seeking resilience and personal development programmes; employers seeking workplace resilience training; and individual users, with eQuoo aimed at teens and young adults and approved for ages 12 and over.

Geography

The company is UK-based, with clients including UK colleges and apprenticeship providers, and eQuoo approvals tied to UK bodies such as the NHS, ORCHA and Ofsted requirements. The 2022 seed round was raised from a US investor explicitly to support expansion into North America, with the company citing investor relationships with major US universities.

History

The company was founded in 2016 and its eQuoo game has been tracked by technology press since that year. Prior to raising outside capital it operated with constrained resources, with the founder describing a period of scaling down and deferred salaries. eQuoo was approved by the UK's National Health Service and at one point distributed by Unilever. The product was rebuilt from a five-week experience into a 52-week programme with multiple storylines, an in-app arcade and a chatbot, a change the founder credited with driving traction ahead of the September 2022 seed round led by Morningside Ventures.

Risks & controversies

The company has acknowledged operating under severe financial constraint before its seed round, including a period without founder salaries. Selling into the education market is described as difficult for startups, and the business depends in part on regulatory drivers such as Ofsted's resilience and personal development requirements. eQuoo also requires good internet access on both mobile and web to be used.